https://www.selleckchem.com/products/foxy5.html
The prognosis of IPMN is better than that of pancreatic cancer. However the risk of recurrence in invasive IPMC was found to be 7-21%. Therefore, IPMC must be surveilled every three months using tumor markers and imaging. Local recurrence in remnant pancreas is usually treated with systemic therapy. The median long-term survival after total pancreatectomy (range 7-24 months) was shown to be better than when chemotherapy alone was used (range 10-13 months). We chose secondary surgery in term of survival time although there are quality of l
Aimer
Commentaire
Partagez
